• Election of Jacques Theurillat as new Chairman of the Board of Directors
• Etienne Jornod appointed Honorary Chairman by the Board of Directors
• Confirmation of all members of the Board of Directors standing for re-election and election of Gilbert Achermann as new member
• Dividend of CHF 2.00 approved
ST GALLEN, Switzerland-Thursday 14 May 2020 [ AETOS Wire ]
(BUSINESS WIRE) -- Regulatory News:
At the 92nd Annual
General Meeting of Vifor Pharma Ltd., shareholders approved all
proposed resolutions put forward by the Board of Directors.
In
view of the current situation and based on Art. 6a of Ordinance 2,
issued by the Swiss Federal Council, regarding measures against
containment of the coronavirus (COVID-19), shareholders were not
permitted to attend the event in person. Shareholders exercised their
rights exclusively through the independent proxy and 69% of the share
capital was represented.
Shareholder approvals
Shareholders
approved the 2019 Vifor Pharma Annual Report, the Vifor Pharma Ltd.
2019 Annual Financial Statements, and the Vifor Pharma Group 2019
Consolidated Financial Statements as well as an extension of the
Authorized Capital until 14 May 2022 by approving the respective
amendment to the Articles of Association. The maximum possible 2020
remuneration for the Board of Directors and Executive Committee was also
approved, as well as the 2019 Remuneration Report in a consultative
vote. Shareholders discharged the members of the Board of Directors and
the Corporate Executive Committee for the financial year 2019. A
dividend of CHF 2.00, as proposed by the Board of Directors, was
approved and will be paid to shareholders on 20 May 2020.
Board of Directors re-elections
The
Annual General Meeting re-elected all members proposed and elected
Gilbert Achermann as new member of the Board of Directors. Shareholders
also elected Jacques Theurillat as new Chairman of the Board of
Directors, succeeding Etienne Jornod who decided not stand for
re-election after 25 years. The Board of Directors sincerely thanks him
for many years of distinguished service and recognized his long-standing
and successful leadership by appointing him as Honorary Chairman.
The
Board of Directors is now composed of the following members: Jacques
Theurillat (Chairman), Gilbert Achermann, Prof. Dr. hon. Michel Burnier,
Dr. Romeo Cerutti, Dr. Sue Mahony, Kim Stratton and Dr. Gianni
Zampieri.
Remuneration Committee confirmed
The
following members of the Board of Directors were re-elected to the
Remuneration Committee for a term of one year: Prof. Dr. hon. Michel
Burnier, Dr. Romeo Cerutti, and Dr. Sue Mahony.
Vifor Pharma Group is
a global specialty pharmaceuticals company. It aims to become the
global leader in iron deficiency, nephrology and cardio-renal therapies.
The company is the partner of choice for pharmaceuticals and innovative
patient-focused solutions. Vifor Pharma Group strives to help patients
around the world with severe and chronic diseases lead better, healthier
lives. The company develops, manufactures and markets pharmaceutical
products for precision patient care. Vifor Pharma Group holds a leading
position in all its core business activities and consists of the
following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal
Pharma (a joint company with Fresenius Medical Care); and OM Pharma.
Vifor Pharma Group is headquartered in Switzerland, and listed on the
Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For
more information, please visit www.viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005044/en/
Contacts
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
